Novel multiagent chemotherapy for bone marrow relapse of pediatric acute lymphoblastic leukemia

Medical and Pediatric Oncology

Volumn 34, Issue 5, 2000, Pages 313-318

  Leahey, Ann M ^a   Bunin, Nancy J ^a,e   Belasco, Jean B ^a   Meek, Rita ^b,c   Scher, Charles ^d   Lange, Beverly J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Acute lymphoblastic leukemia; Bone marrow transplant; Chemotherapy; Pediatrics; Relapse

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; ASPARAGINASE MACROGOL; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROCORTISONE; IDARUBICIN; METHOTREXATE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; BONE MARROW DISEASE; BONE MARROW TRANSPLANTATION; CANCER RECURRENCE; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HUMAN; INFANT; LEUKEMIA REMISSION; MALE; PRIORITY JOURNAL;

ADOLESCENT; ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; BONE MARROW; BONE MARROW TRANSPLANTATION; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; CHILD, PRESCHOOL; CYTARABINE; DEXAMETHASONE; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IDARUBICIN; INFANT; INJECTIONS, SPINAL; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; NEOPLASM RECURRENCE, LOCAL; REMISSION INDUCTION; VINCRISTINE;

EID: 0034018158     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-911X(200005)34:5<313::AID-MPO1>3.0.CO;2-Q     Document Type: Article

References (38)

1. Reiter A, Schrappe M, Ludwig W-D, et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 1994;84:3122-3133.
2. Schorin MA, Blattner S, Gelber RD, et al. Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber Cancer Institute/Children's Hospital acute lymphoblastic leukemia consortium protocol 85-01. J Clin Oncol 1994;12:740-747.
3. Lange B, Sather H, Weetman R, et al. Double delayed intensification improves outcome in moderate risk pediatric acute lymphoblastic leukemia (ALL): a Childrens Cancer Group study, CCG-1891. Blood 1997:90(Suppl 1):559a.
4. Mahoney DH, Shuster J, Nitschke R, et al. Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group phase III trial. J Clin Oncol 1998;16:246-254.
5. Evans WE, Relling MV, Rodman JH, et al. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 1998;338:449-505.
6. Nachman JB, Sather HN, Sensel MG, et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med 1998;338:1663-1671.
7. Henze G, Fengler R, Hartmann R, et al. Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85). A relapse study of the BFM group. Blood 1991;78:1166-1172.
8. Gaynon PS, Chappell RJ, Willoughby ML, et al. Survival after relapse in childhood acute lymphoblastic leukemia: impact of site and time to first relapse - the Children's Cancer Group experience. Cancer 1998;82:1387-1395.
9. Wheeler K, Richards S, Bailey C, Chessells J. Comparison of bone marrow transplant and chemotherapy for relapsed acute lymphoblastic leukemia: the MRC UKALL X experience. Br J Haematol 1998;101:94-103.
10. Belasco JB, Luerry N, Scher C. Multiagent chemotherapy in relapsed acute lymphoblastic leukemia in children. Cancer 1990;66: 2492-2497.
11. Bennett JM, Catovsky D, Daniel M-T, et al. Proposals for the classification of the acute leukemias. French-American-British (FAB) Co-operative Group. Br J Haematol 1976;33:451-458.
12. Tubergen DG, Cullen JW, Boyett JM, et al. Blasts in CSF with a normal cell count do not justify alteration of therapy for acute lymphoblastic leukemia in remission: a Childrens Cancer Group study. J Clin Oncol 1994;12:273-278.
13. Smith M, Arthur D, Camitta B, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 1996;14:18-24.
14. Gaynon PS, Steinherz PG, Bleyer WA, et al. Intensive therapy for children with acute lymphoblastic leukemia and unfavorable presenting features. Early conclusions of study CCG-106 by the Childrens Cancer Study Group. Lancet 1988;2:921-924.
15. Steinherz PG, Gaynon P, Miller DR, et al. Improved disease-free survival of children with acute lymphoblastic leukemia at high risk for early relapse with the New York regimen - a new intensive therapy protocol: a report from the Childrens Cancer Study Group. J Clin Oncol 1986;4:744-752.
16. Kaplan G and Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:454-481.
17. Rivera GK, Hudson MM, Liu Q, et al. Effectiveness of intensified rotational combination chemotherapy for late hematologic relapse of childhood acute lymphoblastic leukemia. Blood 1996;88:831-837.
18. Sadowitz, PD, Smith SD, Shuster J, et al. Treatment of late bone marrow relapse in children with acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood 1993;81:602-609.
19. Buchanon GR, Rivera GL, Boyett JM, et al. Reinduction therapy in 297 childrenwith acute lymphoblastic leukemia in first bone marrow acute relapse: a Pediatric Oncology Group study. Blood 1988;72:1286-1292.
20. Feig SA, Krailo MD, Harris RE, et al. Determination of the maximum tolerated dose of idarubicin when used in a combination chemotherapy program of reinduction of childhood ALL at first marrow relapse and a preliminary assessment of toxicity compared to that of daunorubicin: a report from the Childrens Cancer Study Group. Med Pediatr Oncol 1992;20:124-129.
21. Billett AL, Pollock BH, Abshire TC, Buchanon GR. Outcome of children with B-lineage acute lymphoblastic leukemia in first bone marrow relapse. Blood 1997;90:332a.
22. Reid JM, Pendergrass TW, Krailo MD, et al. Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: a Childrens Cancer Study Group Report. Cancer Res 1990;50:6525-6528.
23. Vogler WR, Velez-Garcia E, Weiner RS, et al. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group study. J Clin Oncol 1992;10:1103-1111.
24. Wiernik PH, Banks PL, Case DC, et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 1992;79:313-319.
25. Balis FM, Lester CM, Chrousos GP, et al. Differences in cerebrospinal fluid penetration of corticosteroids: possible relationship to the prevention of meningeal leukemia. J Clin Oncol 1987;5: 202-207.
26. Jones B, Freeman AI, Shuster JJ, et al. Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemia. Med Pediatr Oncol 1991;19:269-275.
27. Veerman AJP, Mahlen K, Kamps WA, et al. Dutch Childhood Leukemia Study Group: early results of Study VI (1984-1988). Hamatol Bluttransfus 1990;33:473-477.
28. Killander D, Dohlwitz A, Engstedt L, et al. Hypersensitive reactions and antibody formation during L-asparaginase treatment of children and adults with acute leukemia. Cancer 1976;37:220-228.
29. Cheung NK, Chau IY, Coccia PF. Antibody response to E. coli asparaginase. Am J Pediatr Hematol Oncol 1986;8:99-104.
30. Kurtzberg J, Asselin B, Poplack D, et al. Antibodies to asparaginase alter pharmacokinetics and decrease enzyme activity in patients on asparaginase therapy. Proc AACR 1993;34:304a.
31. Welte K, Reiter A, Mempel K, et al. A randomized phase-III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Blood 1996; 87:3143-3150.
32. Tubergen DG, Gilchrist GS, O'Brien RT, et al. Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a Children's Cancer Group phase III trial. J Clin Oncol 1993;11:527-537.
33. Wells RJ, Feusner J, Devney R, et al. Sequential high-dose cytosine arabinoside-asparaginase treatment in advanced childhood leukemia. J Clin Oncol 1985;3:998-1004.
34. Esumi N, Todo S, Arakawa S, et al. Etoposide and cytosine arabinoside combination chemotherapy for refractory acute lymphocytic leukemia in childhood. J Clin Oncol 1986;4:1089-1093.
35. Buhrer C, Hartmann R, Fengler R, et al. Importance of effective central nervous system therapy in isolated bone marrow relapse of childhood acute lymphoblastic leukemia. Blood 1994;83:3468-3472.
36. Bostrom B, Gaynon PS, Sather H, et al. Dexamethasone decreases central nervous system relapse and improves event-free survival in lower risk acute lymphoblastic leukemia. Proc ASCO 1998;17: 527a.
37. Barrett AJ, Horowitz MM, Pollock BH, et al. Bone marrow transplants from HLA-identical siblings as compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission. N Engl J Med 1994;331:1253-1258.
38. Uderzo C, Valsecchi MG, Bacigalupo A, et al. Treatment of childhood acute lymphoblastic leukemia in second remission with allogeneic bone marrow transplantation and chemotherapy: ten-year experience of the Italian Bone Marrow Transplantation Group and the Italian Pediatric Hematology Oncology Association. J Clin Oncol 1995;13:352-358.